• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why NICE Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

    8/17/23 12:26:44 PM ET
    $AHCO
    $AHI
    $AKTX
    $AKU
    Medical/Nursing Services
    Health Care
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $AHCO alert in real time by email

    Gainers

    • PhenomeX Inc. (NASDAQ:CELL) shares surged 138.3% to $0.9532. Bruker Corporation and PhenomeX reported a $108 million definitive agreement for Bruker to acquire PhenomeX in an all-cash transaction for $1 per share.
    • Tivic Health Systems, Inc. (NASDAQ:TIVC) shares jumped 39.1% to $0.0932. Tivic Health Systems shares jumped 80% on Wednesday after the company announced its funded study started enrollment for its non-invasive bioelectronic device approach to vagus nerve stimulation.
    • Sunlight Financial Holdings Inc. (NYSE:SUNL) climbed 36.9% to $0.2101 after declining 8% on Wednesday.
    • Advanced Health Intelligence Ltd. (NASDAQ:AHI) shares rose 30.2% to $5.00. Advanced Health Intelligence said it obtained overseas R&D reimbursement under Australia's research and development tax incentive scheme.
    • Troika Media Group, Inc. (NASDAQ:TRKA) climbed 29% to $1.3794.
    • LSI Industries Inc. (NASDAQ:LYTS) gained 21.8% to $15.55 following better-than-expected fourth-quarter results.
    • BioNexus Gene Lab Corp. (NASDAQ:BGLC) surged 22.2% to $0.88.
    • ETAO International Co., Ltd. (NASDAQ:ETAO) rose 21% to $0.5600.
    • Ascent Solar Technologies, Inc. (NASDAQ:ASTI) gained 18.8% to $0.0799.
    • Super Group (SGHC) Limited (NASDAQ:SGHC) jumped 18.7% to $3.4785 following strong quarterly results.
    • Catalyst Biosciences, Inc. (NASDAQ:CBIO) jumped 16.2% to $0.51.
    • Recruiter.com Group, Inc. (NASDAQ:RCRT) gained 15.1% to $0.2139. Job Mobz announced plans to acquire iconic Recruiter.com brand in cash and stock deal.
    • Gambling.com Group Limited (NASDAQ:GAMB) gained 14.3% to $14.51 as the company posted upbeat second-quarter results and raised FY23 guidance.
    • LQR House Inc. (NASDAQ:LQR) surged 13.5% to $1.93.
    • Modular Medical, Inc. (NASDAQ:MODD) shares gained 13.2% to $1.1550 after the company announced a partnership with Phillips-Medisize to expand insulin delivery alternatives.
    • Datasea Inc. (NASDAQ:DTSS) rose 10.3% to $0.59. Datasea announced a $4 million private placement priced at a 125% premium to market at $1.35 per share.
    • The Children's Place, Inc. (NASDAQ:PLCE) jumped 9.4% to $29.01. Children's Place reported a second-quarter FY23 sales decline of 9.3% year-on-year to $345.59 million, beating the analyst consensus of $342.64 million.
    • Avnet, Inc. (NYSE:AVT) gained 9.6% to $49.28 following strong quarterly results.
    • Triumph Group, Inc. (NYSE:TGI) rose 8.1% to $9.04.
    • Knightscope, Inc. (NASDAQ:KSCP) gained 6.8% to $1.2694 after falling 10% on Wednesday. The company recently posted upbeat quarterly results.

    Losers

    • Creative Realities, Inc. (NASDAQ:CREX) shares fell 35.6% to $1.9050 after the company reported pricing of $6 million public offering of 3 million shares of common stock at $2 per share.
    • EMCORE Corporation (NASDAQ:EMKR) fell 35.6% to $0.4889 after the company reported pricing of $15.8 million public offering.
    • Tremor International Ltd (NASDAQ:TRMR) fell 29.6% to $4.41 after the company reported financial and operating results for the three and six months ended June 30, 2023.
    • China Liberal Education Holdings Limited (NASDAQ:CLEU) fell 22.7% to $0.3363.
    • Amyris, Inc. (NASDAQ:AMRS) fell 21.3% to $0.0630.
    • Natural Alternatives International, Inc. (NASDAQ:NAII) fell 21.3% to $5.49. Natural Alternatives announced temporary closure of its new facility in Carlsbad, California.
    • Check-Cap Ltd. (NASDAQ:CHEK) fell 20.8% to $2.4374. Keystone Dental Holdings and Check-Cap entered into definitive business combination agreement.
    • KULR Technology Group, Inc. (NYSE:KULR) shares tumbled 18.4% to $0.8811 after the company reported second-quarter financial results and announced a proposed public offering of common stock.
    • Wolfspeed, Inc. (NYSE:WOLF) fell 18.4% to $43.40 after the company reported mixed fourth-quarter financial results and issued first-quarter adjusted EPS guidance below estimates.
    • G Medical Innovations Holdings Ltd (NASDAQ:GMVD) fell 18.2% to $0.1551.
    • Hawaiian Electric Industries, Inc. (NYSE:HE) fell 17.7% to $11.70 following a report suggesting the company is facing multiple lawsuits alleging negligence over the Maui fires and is intalks with financial restructuring firms.
    • Novo Integrated Sciences, Inc. (NASDAQ:NVOS) declined 16.3% to $0.1516.
    • Akari Therapeutics, Plc (NASDAQ:AKTX) fell 14.4% to $3.21.
    • Asure Software, Inc. (NASDAQ:ASUR) fell 14.2% to $11.89 after the company reported pricing of public offering of common stock.
    • AdaptHealth Corp. (NASDAQ:AHCO) fell 13.8% to $11.61.
    • UroGen Pharma Ltd. (NASDAQ:URGN) fell 12.9% to $18.70.
    • Calliditas Therapeutics AB (NASDAQ:CALT) declined 11.5% to $16.36 following second-quarter results..
    • Gold Fields Limited (NYSE:GFI) fell 11.4% to $11.27 as the company reported a decline in EPS for the half year.
    • CVS Health Corporation (NYSE:CVS) declined 10.6% to $64.98 following reports that Blue Shield of California plans to drop CVS's Caremark as its pharmacy benefit manager.
    • Digital Brands Group, Inc. (NASDAQ:DBGI) fell 10.3% to $0.70 after jumping 91% on Wednesday.
    • NICE Ltd. (NASDAQ:NICE) fell 9.7% to $190.96 after the company reported second-quarter financial results and issued guidance.
    • Akumin Inc. (NASDAQ:AKU) shares fell 9.5% to $0.1511 after jumping 22% on Wednesday.
    • Madison Square Garden Sports Corp. (NYSE:MSGS) fell 7.1% to $190.99 following mixed fourth-quarter results and a decline in revenues.

    Now Read This: Ethereum Tumbles Below $1,800 Following Jobless Claims Data; Sei Becomes Top Loser

    Get the next $AHCO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHCO
    $AHI
    $AKTX
    $AKU

    CompanyDatePrice TargetRatingAnalyst
    Crescent Biopharma Inc.
    $CBIO
    1/28/2026$35.00Overweight
    Piper Sandler
    Crescent Biopharma Inc.
    $CBIO
    1/21/2026$35.00Buy
    Guggenheim
    Hawaiian Electric Industries Inc.
    $HE
    1/20/2026$12.50Hold → Underperform
    Jefferies
    Akari Therapeutics plc
    $AKTX
    1/5/2026$1.00Buy
    Ladenburg Thalmann
    NICE Ltd
    $NICE
    12/8/2025$120.00Outperform → Neutral
    Wedbush
    Gambling.com Group Limited
    $GAMB
    11/14/2025Buy → Neutral
    BTIG Research
    Gold Fields Limited
    $GFI
    10/28/2025$50.00Buy
    Citigroup
    Gold Fields Limited
    $GFI
    10/23/2025$62.00Overweight
    Analyst
    More analyst ratings

    $AHCO
    $AHI
    $AKTX
    $AKU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Crescent Biopharma with a new price target

    Piper Sandler initiated coverage of Crescent Biopharma with a rating of Overweight and set a new price target of $35.00

    1/28/26 7:10:21 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Crescent Biopharma with a new price target

    Guggenheim initiated coverage of Crescent Biopharma with a rating of Buy and set a new price target of $35.00

    1/21/26 8:54:45 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hawaiian Electric downgraded by Jefferies with a new price target

    Jefferies downgraded Hawaiian Electric from Hold to Underperform and set a new price target of $12.50

    1/20/26 9:08:47 AM ET
    $HE
    Electric Utilities: Central
    Utilities

    $AHCO
    $AHI
    $AKTX
    $AKU
    SEC Filings

    View All

    BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

    2/23/26 8:35:38 AM ET
    $BGLC
    Medical Specialities
    Health Care

    SEC Form 144 filed by Madison Square Garden Sports Corp.

    144 - Madison Square Garden Sports Corp. (0001636519) (Subject)

    2/20/26 2:30:23 PM ET
    $MSGS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form 6-K filed by Gold Fields Limited

    6-K - GOLD FIELDS LTD (0001172724) (Filer)

    2/20/26 9:45:14 AM ET
    $GFI
    Precious Metals
    Basic Materials

    $AHCO
    $AHI
    $AKTX
    $AKU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

    Submission status for CALLIDITAS THERAPEUTICS AB's drug TARPEYO (ORIG-1) with active ingredient BUDESONIDE has changed to 'Approval' on 12/15/2021. Application Category: NDA, Application Number: 215935, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/20/21 3:40:41 PM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHCO
    $AHI
    $AKTX
    $AKU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO/Chairman Ledoux Mark A bought $11,604 worth of shares (4,500 units at $2.58), increasing direct ownership by 3% to 154,721 units (SEC Form 4)

    4 - NATURAL ALTERNATIVES INTERNATIONAL INC (0000787253) (Issuer)

    2/20/26 6:05:52 PM ET
    $NAII
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Operating Officer Handley Michael K converted options into 8,824 shares (SEC Form 4)

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    2/20/26 4:19:42 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Peltz Nelson

    4 - Madison Square Garden Sports Corp. (0001636519) (Issuer)

    2/19/26 4:23:38 PM ET
    $MSGS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AHCO
    $AHI
    $AKTX
    $AKU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AHCO
    $AHI
    $AKTX
    $AKU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board

    TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Olga Anczukow, Ph.D. to its Scientific Advisory Board (SAB). Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics commented, "Dr. Anczukow is a leading authority in RNA splicing and cancer biology, an area of growing importance for the development of next-generation therapeutics. Her scientific rigor, translational mindset, and experience advancing RNA-focused discoveries toward clinical relevance make her an outstandin

    2/23/26 8:50:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

    Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), today announced the completion of a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd. ("Chemrex"). As part of this restructuring, Chemrex's board has been streamlined to two directors: Matthew L. Barsing, ChairmanAngeline Chong, Chief Financial Officer of BioNexus, Director New officers are expected to be appointed in the coming months. Chemrex remains a wholly owned private subsidiary of BioNexus and operates un

    2/23/26 8:30:00 AM ET
    $BGLC
    Medical Specialities
    Health Care

    UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026

    PRINCETON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2025 financial results on Monday, March 2nd , 2026, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days. About UroGen Pharma

    2/23/26 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO/Chairman Ledoux Mark A bought $11,604 worth of shares (4,500 units at $2.58), increasing direct ownership by 3% to 154,721 units (SEC Form 4)

    4 - NATURAL ALTERNATIVES INTERNATIONAL INC (0000787253) (Issuer)

    2/20/26 6:05:52 PM ET
    $NAII
    Medicinal Chemicals and Botanical Products
    Health Care

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Fairmount Funds Management Llc bought $18,237,600 worth of Ordinary Shares (1,360,000 units at $13.41) (SEC Form 4)

    4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)

    12/8/25 4:30:15 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHCO
    $AHI
    $AKTX
    $AKU
    Financials

    Live finance-specific insights

    View All

    UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026

    PRINCETON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2025 financial results on Monday, March 2nd , 2026, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days. About UroGen Pharma

    2/23/26 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avnet Declares Regular Quarterly Dividend

    Avnet, Inc. (Nasdaq: AVT), a leading global technology solutions provider, announced that its Board of Directors has approved a regular quarterly cash dividend of $0.35 per share. The dividend will be paid on March 18, 2026, to shareholders of record as of the close of business on March 4, 2026. About Avnet As a leading global technology distributor and solutions provider, Avnet has served customers' evolving needs for more than a century. Through regional and specialized businesses around the world, we support customers and suppliers at every stage of the product lifecycle. We help companies adapt to change and accelerate the design and supply stages of product development. With a uniq

    2/19/26 7:00:00 PM ET
    $AVT
    Electronic Components
    Technology

    Gambling.com Group to Report 2025 Fourth Quarter and Full Year Results on March 12 and Host Conference Call and Webcast

    Gambling.com Group Limited (NASDAQ:GAMB) ("Gambling.com Group" or the "Company"), a fast-growing provider of marketing and sports data services for the global online gambling industry, today announced it will release its 2025 fourth quarter and full year results before the market opens on Thursday, March 12, 2026, and host a conference call and simultaneous webcast at 8:00 a.m. ET that day. During the call, Gambling.com Group Chief Executive Officer and Co-founder, Charles Gillespie, and Chief Financial Officer, Elias Mark, will review the Company's financial results and provide a business update, followed by a question-and-answer session. Both the call and webcast are open to the public

    2/19/26 7:30:00 AM ET
    $GAMB
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AHCO
    $AHI
    $AKTX
    $AKU
    Leadership Updates

    Live Leadership Updates

    View All

    Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board

    TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Olga Anczukow, Ph.D. to its Scientific Advisory Board (SAB). Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics commented, "Dr. Anczukow is a leading authority in RNA splicing and cancer biology, an area of growing importance for the development of next-generation therapeutics. Her scientific rigor, translational mindset, and experience advancing RNA-focused discoveries toward clinical relevance make her an outstandin

    2/23/26 8:50:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

    Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), today announced the completion of a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd. ("Chemrex"). As part of this restructuring, Chemrex's board has been streamlined to two directors: Matthew L. Barsing, ChairmanAngeline Chong, Chief Financial Officer of BioNexus, Director New officers are expected to be appointed in the coming months. Chemrex remains a wholly owned private subsidiary of BioNexus and operates un

    2/23/26 8:30:00 AM ET
    $BGLC
    Medical Specialities
    Health Care

    Wolfspeed Strengthens Global Sales Leadership with Addition of Semiconductor Leader, Stefan Steyerl, as VP of Sales, EMEA

    Wolfspeed, Inc. (NYSE:WOLF), a global leader in silicon carbide technology and manufacturing, today announced the appointment of Stefan Steyerl as vice president of sales, EMEA. Effective March 1, 2026, Steyerl will develop and execute Wolfspeed's regional sales strategy, driving adoption of silicon carbide solutions across automotive, industrial, and energy markets as Wolfspeed accelerates the adoption of silicon carbide technology to expand its market footprint and deliver revenue growth across the region. Steyerl brings more than 25 years of experience in the semiconductor industry, with a proven track record of building high-performance teams and achieving revenue growth across global

    2/17/26 8:00:00 AM ET
    $WOLF
    Semiconductors
    Technology

    $AHCO
    $AHI
    $AKTX
    $AKU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    12/6/24 4:00:28 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Wolfspeed Inc.

    SC 13G/A - WOLFSPEED, INC. (0000895419) (Subject)

    12/6/24 11:56:48 AM ET
    $WOLF
    Semiconductors
    Technology

    Amendment: SEC Form SC 13G/A filed by Wolfspeed Inc.

    SC 13G/A - WOLFSPEED, INC. (0000895419) (Subject)

    12/5/24 2:20:23 PM ET
    $WOLF
    Semiconductors
    Technology